Skip to main content
padlock icon - secure page this page is secure

Free Content Blood-Brain-Barrier Imaging in Brain Tumors: Concepts and Methods

Download Article:
(HTML 74 kb)
(PDF 5,281.4 kb)
Malignant gliomas are often very heterogeneous tumors with complex vasculature, frequently exhibiting angiogenesis and increased vascular permeability. In vivo measurement of the tumor vessel permeability can serve as a potential imaging biomarker to assess tumor grade and aggressiveness. It can also be used to study the response of tumors to various therapies, especially antiangiogenic therapy. Central to the concept of permeability is a thorough knowledge of the BBB and its role in brain tumors and angiogenesis. Much work has been done in the past to understand the structural/molecular composition of the BBB and the role it plays in various pathologic processes, including brain tumors. Various imaging techniques have also been used to evaluate BBB leakiness in brain tumors because higher tumor vascular leakiness is known to be associated with higher grade and malignant potential of the tumor and hence poor patient prognosis. These imaging techniques range from routine postcontrast T1-weighted images to measurement of vascular permeability using various quantitative or semiquantitative indices based on multicompartment pharmacokinetic models. The purpose of this article is to discuss BBB anatomy; various clinically available imaging techniques to evaluate tumor vascular leakiness (perfusion imaging), including their advantages and limitations; as well as a brief discussion of the clinical utility of measuring vascular permeability in brain tumors. We will also discuss the various permeability-related indices along with the pharmacokinetic models to simplify the “nomenclature soup.”
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: BBB = Blood-Brain Barrier; CBF = cerebral blood flow; CBV = cerebral blood volume; DCE = dynamic contrast-enhanced; DSC = dynamic-susceptibility contrast; FDA = US Food and Drug Administration; GBM = glioblastoma multiforme; HIF-1α = hypoxia-inducible factor; IRF = impulse residue function; Ktrans = forward transfer coefficient; MSIVP = maximum slope of enhancement in the initial vascular phase; MVCP = microvascular cellular proliferation; MVD = microvascular density; PCT = perfusion CT; PS = permeability surface-area product; PSR = percentage signal-intensity recovery; SDF-1 = stromal derived factor-1; TDLs = tumefactive demyelinating lesions; TVA = total vascular area; VEGF = vascular endothelial growth factor; VEGFR-2 = vascular endothelial growth factor receptor-2; kep or kb = reverse transfer constant; nIAUC = initial area under the normalized time-intensity curve; nSDEP = normalized slope of the delayed equilibrium phase; rCBV = relative cerebral blood volume; rPSR = relative percentage signal-intensity recovery

Document Type: Research Article

Publication date: June 1, 2012

More about this publication?
  • Neurographics is the peer-reviewed, bimonthly educational journal of the American Society of Neuroradiology. The journal comprises articles selected from material presented at the ASNR Annual Meeting. Neurographics also publishes other high-quality submissions that are primarily educational and have a high emphasis on a pictorial approach. Neurographics offers CME credit for reading review articles and completing quiz-based self-assessment activities.

    Visit to view all available CME courses.

  • Editorial Board
  • Information for Authors
  • Membership Information
  • Order a Print Copy
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more